<DOC>
	<DOC>NCT00586508</DOC>
	<brief_summary>The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment recurrent malignant gliomas.</brief_summary>
	<brief_title>Trial of Enzastaurin and Bevacizumab in Adults With Recurrent Malignant Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patient must be at least 18 years old Patient must have been diagnosed with a recurrent brain tumor by MRI scan Patient must be willing to practice adequate contraception Patient must be able to swallow the Enzastaurin tablets whole and receive Bevacizumab intravenously Patient must agree to use the study drug only as instructed by your study doctor and staff. Women who are pregnant or breastfeeding Patients who have significant heart, liver, kidney, or psychiatric disease Patients who have an active infection Patients who have any recent bleeding in the brain Patients who are taking any anticoagulation or antiplatelet medication (including aspirin, nonsteroidal antiinflammatories, COX2 inhibitors)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>